The European Dermatology Forum (EDF) has issued the first evidence-based guidance on the management of actinic keratosis (AK) across Europe.
The guidelines, endorsed by the European Union of Medical Specialists, identify two licensed treatments for AK with the highest level of evidence to support their use, diclofenac sodium (Solaraze 3% Gel) and photodynamic therapy (both demonstrating an evidence level of 2b).
The use of cryotherapy, a frequently used treatment, is associated with a lower overall evidence level (ranging from 2b-3b) than the methods mentioned above. The guidelines highlight the concept of field cancerisation: AK can occur as single lesions but more commonly affects a complete “field” of sun exposed skin. AK in the UK is widespread, affecting 34% in men and 18% in women aged over 70.
